1. Japanese Respiratory Society. The JRS guidelines for management of ACO 2018. Tokyo: Medical Review; 2018.
2. Barrecheguren M, Esquinas C, Miravitlles M. The asthma COPD overlap syndrome (ACOS). Opportunities and challenges. Curr Opin Pulm Med. 2015;21(9):74-9.
3. Miravitlles M, Alvarez-Gutierrez FJ, Calle M, Casanova C, Cosio BG, López-Viña A, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J. 2017;49(5):1700068.
4. Plaza V, Alvarez F, Calle M, Casanova C, Cosío BG, López-Viña A, et al. Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA). Arch Bronconeumol. 2017;53(8):443-9.
5. Pérez-de-Llano L, Cosio BG; CHACOS study group. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respir Res. 2017;18(6):1-4.
6. Toledo-Pons N, van Boven JF, Román-Rodríguez M, Pérez N, Valera Felices JL, Soriano JB, et al. ACO: time to move from the description of different phenotypes to the treatable traits. PLOS ONE 2019;14(1):e0210915.
7. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35-48.
8. Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69-84.
9. NA Hanania, BE Chipps, NM Griffin, B Yoo, A Iqbal, TB Casale. Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143(12):1629-33.
10. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613-29.
11. Pérez de Llano L, Dacal Rivas D, Marina Malanda N, Plaza Moral V, Gullón Blanco JA, Muñoz-Esquerre M, et al. The response to biologics is better in patients with severe asthma than in patients with asthma-COPD overlap syndrome. J Asthma Allergy. 2022;15(4):363-9.
12. Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48(21):664-73.
13. Shiota S, Katoh M, Fujii M, Aoki S, Matsuoka R, Fukuchi Y: Predictive equations and the reliability of the impulse oscillatory system in Japanese adult subjects. Respirology. 2005;10: 310–315.
14. Kodaka N, Yamagishi T, Watanabe K, Kishimoto K, Nakano C, Oshio T, et al. Evaluation of inhaled procaterol for potential assist use in patients with stable chronic obstructive pulmonary disease. Med Princ Pract. 2018;27(4):350-5.
15. Barranco P, Phillips-Angles E, Dominguez-Ortega J, Quirce S. Dupilumab in the management of moderate-to-severe asthma: the data so far. Clin Risk Manag. 2017;13(5):1139-49.
16. Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: basic aspects and applications to allergic diseases. Allergol Int. 2020;69(5):187-96.
17. Cosío BG, Dacal D, Pérez de Llano L. Asthma-COPD overlap: identification and optimal treatment. Ther Adv Respir Dis. 2018;12(5):1753466618805662.
18. Van Tho N, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): a diagnostic challenge. Respirology. 2015;21(5):410-8.